A study to compare the costs between intravenous Magnesium Sulfate and placebo in acute exacerbations of chronic obstructive pulmonary disease
Not Applicable
Completed
- Conditions
- Health Condition 1: - Health Condition 2: null- acute exacerbations of Chronic obstructive pulmonary disease
- Registration Number
- CTRI/2018/04/013309
- Lead Sponsor
- Kempegowda institute of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
Subjects of either gender between 18- 65 years diagnosed as COPD grade 2/3 (GOLD criteria) presenting with symptoms of acute exacerbations and not requiring ventilation
Exclusion Criteria
subjects with severe COPD exacerbations requiring invasive ventilation and patients in respiratory failure and altered sensorium
patients with TB, Bronchiectasis
patients with a history of cerebrovascular disease,hepatic, cardiac, renal dysfunction, uncontrolled diabetes mellitus were excluded
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method primary outcome- efficacy of Magnesium sulfate was estimated by measuring, PEFR(peak expiratory flow rates) at 0,15,30,45 minsTimepoint: primary outcome- efficacy of Magnesium sulfate was estimated by measuring, PEFR(peak expiratory flow rates) at 0,15,30,45 mins
- Secondary Outcome Measures
Name Time Method Costs were estimated based on direct medical resources used for management of exacerbationsTimepoint: on discharge all hospital related costs were calculated